Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

Published byΆκανθα Κακριδής Modified over 5 years ago

Similar presentations

Presentation on theme: "A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,"— Presentation transcript:

1 A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety, MD, Pamela A. Frischmeyer-Guerrerio, MD, PhD, Corinne A. Keet, MD, MS, Mark Gorelik, MD, John Schroeder, PhD, Robert G. Hamilton, PhD, Robert A. Wood, MD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 5, Pages e6 (May 2015) DOI: /j.jaci Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 CONSORT diagram. Time points include T1 (baseline), T3 (end of dose build-up), T4 and T5 (after 6 and 12 months of maintenance, subjects unblinded at T5), T6 (completion of additional 6 months of maintenance), and T7 (4 weeks off therapy). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Change in cumulative OFC dose after SLIT (A) and OIT (B). Red lines indicate active SLIT, blue lines indicate active OIT, and purple lines represent combined SLIT and OIT after unblinding. Open circles represent subjects with sustained unresponsiveness. Between groups, there were significantly greater changes in OFC thresholds with OIT compared with SLIT (P = .008 and P = .01 after 6 and 12 months of maintenance). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Change in end point skin test results after SLIT (A) and OIT (B). Red lines indicate active SLIT, blue lines indicate active OIT, and purple lines represent combined SLIT and OIT after unblinding. Open circles represent subjects with sustained unresponsiveness. Comparison of the SLIT and OIT groups revealed similar changes in skin test results over time, with the exception of greater changes in the OIT group at T4 (P = .03). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Change in peanut-specific IgE levels after SLIT (A) and OIT (B). Red lines indicate active SLIT, blue lines indicate active OIT, and purple lines represent combined SLIT and OIT after unblinding. Open circles represent subjects with sustained unresponsiveness. By 6 months, the decrease in peanut IgE levels was greater in the OIT group, and this difference widened by 12 months (P = .07 and P = .007, respectively). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Change in peanut-specific IgG4 levels after SLIT (A) and OIT (B). Red lines indicate active SLIT, blue lines indicate active OIT, and purple lines represent combined SLIT and OIT after unblinding. Open circles represent subjects with sustained unresponsiveness. Between groups, there was overall a greater change from baseline in peanut-specific IgG4 levels over time in the OIT group compared with the SLIT group at all time points (end of dose build-up [P = .003] after 6 and 12 months of maintenance [P < .001]). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E1 Study schematic indicating treatment groups and assignment of open-label treatment after the 12-month OFC. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E2 Change in SPT responses (median wheal size) for other food and environmental allergens after SLIT (A) and OIT (B). See Table E4 for P values for the individual allergens at each time point. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,"

Similar presentations

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
Omalizumab facilitates rapid oral desensitization for peanut allergy

Omalizumab facilitates rapid oral desensitization for peanut allergy
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Advances in food allergy in 2015

Advances in food allergy in 2015
Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity  Christophe Dupont, MD, PhD,

Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity  Christophe Dupont, MD, PhD,
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood  Zaraquiza Zolkipli, MSc,

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood  Zaraquiza Zolkipli, MSc,
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

Similar presentations

Ads by Google